MyFinsight
Home
Blog
About
Cash and cash
equivalents
$59,443K
(61.49%↑ Y/Y)
Marketable securities
$50,754K
(-52.37%↓ Y/Y)
Prepaid expenses and
other current assets
$5,316K
(5.58%↑ Y/Y)
Total current assets
$115,513K
(-22.16%↓ Y/Y)
Other assets,
long-term
$263K
(-43.32%↓ Y/Y)
Restricted cash
$231K
(-0.43%↓ Y/Y)
Total assets
$116,007K
(-32.51%↓ Y/Y)
Total liabilities and
stockholders equity
$116,007K
(-32.51%↓ Y/Y)
Total liabilities
$58,744K
(7.16%↑ Y/Y)
Total stockholders
equity
$57,263K
(-51.09%↓ Y/Y)
Accumulated deficit
-$499,917K
(-26.60%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$13K
(-156.52%↓ Y/Y)
Total current
liabilities
$46,848K
(88.44%↑ Y/Y)
Debt, long-term
$11,896K
(-60.19%↓ Y/Y)
Additional paid-in capital
$557,186K
(8.84%↑ Y/Y)
Common stock, 0.0001
par value...
$7K
(16.67%↑ Y/Y)
Debt, short-term
$19,673K
Accounts payable
$13,379K
(536.19%↑ Y/Y)
Accrued expenses and
other current...
$7,533K
(-35.34%↓ Y/Y)
Accrued clinical trial
expenses
$6,263K
(-43.62%↓ Y/Y)
Back
Back
Balance Sheet
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)
source: myfinsight.com